1. Pink Sheet
  2. >>Vaccines

BARDA Scales Up COVID-19 Vaccine Manufacturing Capacity With $628m For Emergent BioSolutions

 
• By Bowman Cox

An inflection point arrives as US public sector pharma manufacturing hits 'warp speed' in COVID-19 crisis.

Pharmaceutical manufacturer of vaccines, discovery of the right drug to fight a disease. Vaccine, protection campaign, health. Diseases and cures. 3d rendering. Immunity against diseases
Vaccine capacity secured at warp speed • Source: Shutterstock

A $628m task order the US Health and Human Services Department announced on 1 June for manufacture of COVID-19 vaccines and therapies as part of the Trump administration’s Operation Warp Speed significantly expands a federal partnership with Emergent BioSolutions Inc., a Gaithersburg, MD, contract development and manufacturing organization that focuses on medical countermeasures.

The award, along with a potentially $800m 19 May award to Phlow Corp., a domestic active pharmaceutical ingredient manufacturing start-up based in Richmond, VA, represents an inflection point in the role the US government plays in pharmaceutical manufacturing

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

Mayne’s Nextstellis Promo Wrong To Suggest Better Safety Than Other Contraceptives, FDA Says

 
• By Sue Sutter

A professional slide deck for the drospirenone/estetrol oral contraceptive inappropriately suggests it is safer than other estrogen-containing products and understates risks, Office of Prescription Drug Promotion said in the first “untitled” letter issued since reductions-in-force.

US HHS Deputy Nominee Talks AI, Not FDA, In Confirmation Hearing

 
• By Ramsey Baghdadi

Silicon Valley investor Jim O’Neill’s Senate confirmation hearings showcased the unique background of someone with government and tech experience and avoided discussions of his past statements about lowering the bar for regulatory approval.

US FDA Waiting On Guidance Agenda Future As HHS Seeks Regulation Cuts

 
• By Derrick Gingery

The FDA continues to wait for a decision on whether its priority guidances will be published as HHS asks the public for potential regulation cuts to fulfill President Trump’s executive order.